14+ hour, 43+ min ago   (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...

14+ hour, 43+ min ago   (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...

2+ day, 9+ hour ago   (379+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates in melanoma presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Meredith McKean, MD, MPH: Hi, I am Meredith McKean. I’m a…...

2+ day, 9+ hour ago   (320+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates to Merkel cell carcinoma (MCC) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. McKean describes updates from the STAMP, ADAM, and…...

2+ day, 9+ hour ago   (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....

2+ day, 9+ hour ago   (213+ words) By performing whole‑genome CRISPR screens in heterogeneous co‑cultures, Dr. Kornelia Polyak et al. identified genes that sensitize HER2‑low cells to T‑DXd. In this segment, Dr. Polyak focuses on USP9X and ABCC1, explaining why USP9X stood out as a promising and…...

2+ day, 9+ hour ago   (136+ words) Docwire News Five-Year PHERGain Results Validate pCR-Guided Treatment De-Escalation According to Dr. Antonio Llombart-Cussac, the 5-year PHERGain analysis confirms the long-term safety and effectiveness of a chemotherapy-sparing, response-guided approach in HER2-positive breast cancer, with approximately 91% invasive disease-free survival across the…...

2+ day, 9+ hour ago   (144+ words) Docwire News PHERGain-2: Targeted Therapy Alone Achieves Strong Responses in Early HER2+ Breast Cancer As explained onsite from ESMO Breast Cancer 2026 by Dr. Antonio Llombart-Cussac, PHERGain-2 builds on prior de-escalation research to evaluate a chemotherapy-free, pCR-guided strategy in early HER2-positive breast…...

2+ day, 9+ hour ago   (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...

2+ day, 9+ hour ago   (427+ words) The following transcript has been edited for clarity. Can you elaborate a little on what the results tell us about survodutide’s unique dual glucagon/GLP-1 mechanism? Dr. Le Roux: Yeah, because survodutide acts like an oxyntomodulin analog, a natural gut…...